Viking Therapeutics' stock gained on July 18, 2025, exceeding the S&P 500's daily gain while the medical sector declined.
4 reports, 1 independent
Updated Jul 18
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Viking Therapeutics' stock gained on July 18, 2025, exceeding the S&P 500's daily gain while the medical sector declined.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Keep exploring
The entities involved
-
Viking Therapeutics
company in San Diego, United States
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
Coverage
Newest first; wire copies grouped- ZacksViking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know In the latest close session, Viking Therapeutics, Inc. (VKTX) was up +1.39% at $32.07. This move outpaced the S&P 50
- ZacksViking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $31.29, demonstrating a +2.93% change from the preceding day'
- Unknown outlet
- Unknown outlet